Literature DB >> 27118952

Treatment of Intermediate-Stage Hepatocellular Carcinoma.

Richard S Finn1.   

Abstract

Entities:  

Year:  2015        PMID： 27118952      PMCID： PMC4843044     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Authors:  Jordi Bruix; Jean-Luc Raoul; Morris Sherman; Vincenzo Mazzaferro; Luigi Bolondi; Antonio Craxi; Peter R Galle; Armando Santoro; Michel Beaugrand; Angelo Sangiovanni; Camillo Porta; Guido Gerken; Jorge A Marrero; Andrea Nadel; Michael Shan; Marius Moscovici; Dimitris Voliotis; Josep M Llovet
Journal:  J Hepatol       Date:  2012-06-19       Impact factor: 25.083

Review 2.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 3.  Treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

Review 4.  Intermediate hepatocellular carcinoma: current treatments and future perspectives.

Authors:  J-F Dufour; I Bargellini; N De Maria; P De Simone; I Goulis; R T Marinho
Journal:  Ann Oncol       Date:  2013-04       Impact factor: 32.976

5.  Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.

Authors:  Masatoshi Kudo; Guohong Han; Richard S Finn; Ronnie T P Poon; Jean-Frederic Blanc; Lunan Yan; Jijin Yang; Ligong Lu; Won-Young Tak; Xiaoping Yu; Joon-Hyeok Lee; Shi-Ming Lin; Changping Wu; Tawesak Tanwandee; Guoliang Shao; Ian B Walters; Christine Dela Cruz; Valerie Poulart; Jian-Hua Wang
Journal:  Hepatology       Date:  2014-09-29       Impact factor: 17.425
  5 in total
  1 in total

1.  MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.

Authors:  Chaoyong Tu; Wei Chen; Shuqian Wang; Wei Tan; Jingqiang Guo; Chuxiao Shao; Weilin Wang
Journal:  J Cell Mol Med       Date:  2019-02-23       Impact factor: 5.310
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.